AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial

MT Newswires Live05-14

AstraZeneca (AZN) said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.

The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.

Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.

The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635791532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 15:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635791532","market":"sg","top_or_hot":-1,"title":"AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.</p><p>The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.</p><p>Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.</p><p>The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 15:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.</p><p>The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.</p><p>Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.</p><p>The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2462157665.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635791532","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635791532","pubTimestamp":1778744636,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4588":"碎股","BK4568":"美国抗疫概念","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","AZNH":"ASTRAZENECA PLC ADRhedged","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4007":"制药","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"阿斯利康表示膀胱癌治疗在3期试验中提高了生存率","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNH":0.6,"AZN":1},"content_text":"AstraZeneca (AZN) said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635791532","isCrawlerRequest":true}